Superannuation warning as vulnerable Aussies hit with rogue calls after $50,000 disaster: 'Preyed upon'
CPA Australia superannuation lead Richard Webb (left) said Aussies are getting unsolicited calls after the US tariffs wreaked havoc on accounts across the country, like for Peter Jarratt, who lost $50,000 almost overnight. (Source Supplied)
Australians are being urged to be wary of unsolicited phone calls about their superannuation. Thousands of people across the country have had their nest eggs affected by Donald Trump's tariffs and the global uncertainty around them.
A poll of more than 8,200 Yahoo Finance readers found 72 per cent were scared about the health of their superannuation. Brisbane worker Peter Jarratt told Yahoo Finance he saw $50,000 vanish "overnight" from his super and investments, with the 69-year-old nervous he'll have to delay his retirement as a result.
That has provided the perfect breeding ground for rogue phone calls, where Aussies are "preyed upon" and promised big super boosts to combat the effects of the tariffs.
RELATED
Don't believe the superannuation promises
Financial institution CPA Australia wants Aussies to take the advice with a grain of salt.
'There's a high chance you'll be getting unlicensed financial advice, or these calls could be designed to steal your personal information – or even your superannuation savings,' Richard Webb, CPA Australia's superannuation lead, said.
'Do not make any decisions about your superannuation without first talking to a licensed financial adviser or your superannuation fund.'
Do you have a super or retirement story? Email stew.perrie@yahooinc.com
CPA Australia has revealed the signs to be aware of for these dodgy phone calls:
The call comes from a withheld number or another suspicious-looking number
The caller is vague or attempts to skim over where they are calling from, such as using an acronym
They ask 'have you heard about this' to gauge your level of knowledge about the issue at hand
They create a sense of urgency and try to convince you that you need to act quickly and quote statistics or other 'evidence'
Similarly, if you get a text message out of the blue with the same type of message, don't click on any links provided.
This could open up a gateway to your personal information being stolen.
How much have Australians lost thanks to the tariffs?
Superannuation consultant firm Chant West revealed last month that the median super balanced option fell 1.9 per cent in March and was projected to fall a further 2 per cent in April.
A balanced option is one where 61 to 80 per cent of the money is invested in shares.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Challenges pharma companies face in push into US manufacturing
Yahoo Finance senior health reporter Anjalee Khemlani explains the pharmaceutical industry's push into domestic manufacturing in the US, as a reshoring tactic to tighten up the supply chain. Planning can still take several years to be finalized and face cost barriers amid tariffs. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Well, the pharmaceutical industry has its eye on US-based manufacturing. What does that mean near term for the sector? Yahoo Finance's Anjali Comlani joins us now with more on obviously there's been a big push in many different industries to reshore manufacturing. Um, pharmaceutical companies seem pretty much on board with this, but what does it look like in actuality? Well, it actually is that they're on board and they have been, but not for the reasons that have anything to do with tariffs. This is not something new for them. Really, the pharma industry has been pushing for reshoring since the COVID-19 pandemic. And that's because that's when they first learned of the risk of the supply chain. So what we have now is this like grand big number, 270 billion plus in investment dollars that has been announced by some of the major companies in the last few months. And that is because of projects that have already been on the table or new projects that they may have pushed up the launch for announcement for in light of the Trump administration pressuring with tariffs and the threat of tariffs. The idea being that if they commit to these reshoring projects, then they will somehow get out of the tariffs. Now, that doesn't seem to be panning out. We know that the Trump administration has said that they will be announcing some sort of tariff soon. So all eyes on that, and what that means then for these companies, will they continue to commit? Will they slow down the pace of them? We're going to sit there and and and wait for them to tell us. But in the meantime, just take a look at the pros and cons of what this reshoring really looks like. On the pro side, you have a majority of drugs currently being produced in Europe and Asia. Europe takes the branded and Asia really for the generics. Now, US really uses a lot of generic drugs, so a lot of our reliance is on Asia for that reason. As I mentioned, COVID-19 showed us that the supply chain is at risk, and so bringing it back will help us with that. Also, newer medications, personalized medications, need to be closer to home. And that's one of the reasons why these companies were already focused on reshoring, or rather opening plants here, because there are some newer medications that have maybe shorter shelf lives or need to be closer to the patient. Um, it's just an easier process. Meanwhile, these companies are also looking at patent cliffs. And that's something that would help boost more manufacturing because they need to focus on their R&D pipeline, and that requires more manufacturing for dosing for clinical trials and the like. Now, looking at the disadvantages, uh, costs are up at this current time in part, thanks to tariffs on some of the construction material. Also, the construction area specifically for manufacturing for pharma, they are facing labor shortages and some of them is getting disrupted by immigration. So that's stressing the sector and means that any of these projects could hit snags and pauses. There's also the pressure from the inflation reduction Act and the most favored nations clauses, and how much price absorption the company is has to do, the companies will have to deal with there. Meanwhile, also, the planning takes about three to five years. So if they're looking at rolling out these plans by 2030, um, they should really be on it right about now to make that happen. I also want to talk about, um, some of the areas. One really interesting thing that is happening though with this shift and this focus is I want to take a look at this map right now, which has sort of these established hubs for pharma manufacturing. You know that the West Coast and California, um, as well as the East Coast, North Carolina, that research triangle, New York, New Jersey area, as well as Boston, has been major hub. Texas and Ohio are coming up interestingly enough, as well as a little bit of South Carolina tied to North Carolina, and then Indianapolis. That one's interesting to me because that is all and entirely Eli Lilly. Thanks to the JLP1. So we're seeing some more interest in some different areas. So what I'm interested in seeing is how much that really appeases the Trump administration, which wants to bring back, you know, manufacturing at large, and will it actually succeed in doing that for this industry? That's the question. Yeah. All right. Thank you, Ange. Appreciate it.
Yahoo
3 hours ago
- Yahoo
Warning over $3,480 debt facing millions of Aussies: ‘No choice'
Millions of Australians are turning to credit cards as high mortgage rates and the rising cost of living make it harder to keep up. Credit card debt has jumped to more than $18 billion, the highest level in nearly four years. More than one million Australians have maxed out their available credit and opened a second credit card, new Finder research found. The average balance per consumer is now standing at $3,480. Finder personal finance expert Sarah Megginson told Yahoo Finance living expenses have outstripped earnings and many Aussies were putting the balance on credit cards. RELATED Millennial reveals huge money reality facing nearly one million Aussies Major Coles move to take on Chemist Warehouse, Bunnings, Amazon Centrelink payment change happening next week: 'Will increase' 'With limited savings to absorb those higher costs, many Australians have had no choice but to take on more credit card debt to manage rising costs,' she said. Finder's survey of 1,005 respondents found one in four Australians had switched credit cards or added a new credit card over the past year. One in 10 Aussies did it in pursuit of rewards points, while the same proportion were seeking a lower interest rate. Around 6 per cent had applied for a balance transfer, while 4 per cent were looking for lower transaction fees. Australia's credit card debt rose to $18.13 billion in March, Reserve Bank of Australia data found, with spending hitting new record highs. The total value of credit card transactions rose by $382 million or 1 per cent in the month, and $1.2 billion or 4 per cent compared to the same time a year ago. RBA data shows the average credit card rate over the last 12 months was 18.49 per cent, out of the cards charging interest. That means Australians have paid out nearly $3.3 billion in credit card interest charges in the past year. Findex financial advisor Jess Bell said credit cards can get a 'bad rap' because people don't understand the rules around them. 'I like to use it for my own cashflow in the way that any direct debits are done on credit cards, so I don't have to think about it,' she told Yahoo Finance. "At the end of each month or each statement that's due, we pay it off in full. I forecast all my bills for the year with an added 5, 10 per cent buffer for all my expenses.' She said it was important to have a strategy in place so you can repay your bill each month and avoid paying interest. 'That's where it can be a really good strategy is you don't just spend it on the credit card and not keep putting money away for when the credit card [bill] comes due. That's where people get stuck,' she said. While credit cards can be a common part of some Aussies' day-to-day money habits, others can find themselves in a 'downward debt spiral' due to some bad mistakes. Finder previously found 13 per cent of Aussies had fallen behind on repayments, with 8 per cent 30 days late, 4 per cent 60 days late, and 2 per cent more than 60 days behind. Missed payments will usually incur a late fee and interest charges, which can add up quickly, plus it can have a negative impact on your credit score. Megginson said it was important for Aussies to review their budgets. 'It's crucial for Australians to review their spending, create a realistic budget, and explore lower-cost credit options,' she said. 'A few smart moves now — like consolidating debt or setting repayment goals — can make a big difference in getting back in control.'
Yahoo
6 hours ago
- Yahoo
If You Invested $10K In AvalonBay Communities Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AvalonBay Communities Inc. (NYSE:AVB) is a multifamily real estate investment trust, which develops, redevelops, acquires, and manages distinctive communities in select U.S. markets. The company's stock traded at approximately $161.01 per share 10 years ago. If you had invested $10,000, you could have bought roughly 62 shares. Currently, shares trade at $203.96, meaning your investment's value could have grown to $12,668 from stock price appreciation alone. However, AvalonBay Communities also paid dividends during these 10 years. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Invest Where It Hurts — And Help Millions Heal: AvalonBay Communities' dividend yield is currently 3.43%. Over the last 10 years, it has paid about $64.02 in dividends per share, which means you could have made $3,976 from dividends alone. Summing up $12,668 and $3,976, we end up with the final value of your investment, which is $16,644. This is how much you could have made if you had invested $10,000 in AvalonBay Communities stock 10 years ago. This means a total return of 66.44%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 238.30%. AvalonBay Communities has a consensus rating of "Neutral" and a price target of $221.59 based on the ratings of 25 analysts. The price target implies more than 8% potential upside from the current stock price. Trending: If there was a new fund backed by Jeff Bezos offering a ? On April 30, the company announced its Q1 2025, posting FFO of $2.83, compared to the consensus estimate of $2.81, and revenues of $745.88 million, compared to the consensus of $743.17 million, as reported by Benzinga. The company provided its Q2 2025 guidance, expecting core FFO per share in the range of $2.72 to $2.82, and EPS of $1.78 to $1.88. Check out this article by Benzinga for eight analysts' insights on AvalonBay Communities. Given the expected upside potential, growth-focused investors may find AvalonBay Communities stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.43%. Read Next: Maximize saving for your retirement and cut down on taxes: . , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article If You Invested $10K In AvalonBay Communities Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
